• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估 ClinicalTrials.gov 中美国联邦资助的 COVID-19 临床研究支持研究材料的可发现性。

Evaluating the discoverability of supporting research materials in ClinicalTrials.gov for US federally funded COVID-19 clinical studies.

出版信息

J Med Libr Assoc. 2024 Jul 1;112(3):250-260. doi: 10.5195/jmla.2024.1799. Epub 2024 Jul 29.

DOI:10.5195/jmla.2024.1799
PMID:39308913
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11412123/
Abstract

OBJECTIVE

The objective of this study was to evaluate the discoverability of supporting research materials, including supporting documents, individual participant data (IPD), and associated publications, in US federally funded COVID-19 clinical study records in ClinicalTrials.gov (CTG).

METHODS

Study registration records were evaluated for (1) links to supporting documents, including protocols, informed consent forms, and statistical analysis plans; (2) information on how unaffiliated researchers may access IPD and, when applicable, the linking of the IPD record back to the CTG record; and (3) links to associated publications and, when applicable, the linking of the publication record back to the CTG record.

RESULTS

206 CTG study records were included in the analysis. Few records shared supporting documents, with only 4% of records sharing all 3 document types. 27% of records indicated they intended to share IPD, with 45% of these providing sufficient information to request access to the IPD. Only 1 dataset record was located, which linked back to its corresponding CTG record. The majority of CTG records did not have links to publications (61%), and only 21% linked out to at least 1 results publication. All publication records linked back to their corresponding CTG records.

CONCLUSION

With only 4% of records sharing all supporting document types, 12% sufficient information to access IPD, and 21% results publications, improvements can be made to the discoverability of research materials in federally funded, COVID-19 CTG records. Sharing these materials on CTG can increase their discoverability, therefore increasing the validity, transparency, and reusability of clinical research.

摘要

目的

本研究旨在评估在美国联邦资助的 COVID-19 临床研究记录 ClinicalTrials.gov(CTG)中,支持性研究材料(包括支持文件、个体参与者数据(IPD)和相关出版物)的可发现性。

方法

评估研究注册记录中的(1)支持性文件(包括方案、知情同意书和统计分析计划)的链接;(2)关于如何让非附属研究人员访问 IPD 的信息,以及在适用的情况下,将 IPD 记录链接回 CTG 记录;(3)相关出版物的链接,以及在适用的情况下,将出版物记录链接回 CTG 记录。

结果

共纳入 206 项 CTG 研究记录进行分析。很少有记录共享支持性文件,只有 4%的记录共享了全部 3 种文件类型。27%的记录表示他们打算共享 IPD,其中 45%提供了足够的信息来请求访问 IPD。仅找到了一个数据集记录,该记录链接回其对应的 CTG 记录。大多数 CTG 记录没有出版物链接(61%),只有 21%链接到至少 1 个结果出版物。所有的出版物记录都链接回了他们相应的 CTG 记录。

结论

只有 4%的记录共享了所有支持文件类型,12%的记录提供了足够的信息来访问 IPD,只有 21%的记录有结果出版物,因此可以提高联邦资助的 COVID-19 CTG 记录中研究材料的可发现性。在 CTG 上共享这些材料可以提高它们的可发现性,从而提高临床研究的有效性、透明度和可重复性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26c5/11412123/c394fe9aa14b/jmla-112-3-250-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26c5/11412123/4673c4da9c23/jmla-112-3-250-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26c5/11412123/b05f68c4477c/jmla-112-3-250-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26c5/11412123/c394fe9aa14b/jmla-112-3-250-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26c5/11412123/4673c4da9c23/jmla-112-3-250-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26c5/11412123/b05f68c4477c/jmla-112-3-250-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26c5/11412123/c394fe9aa14b/jmla-112-3-250-g003.jpg

相似文献

1
Evaluating the discoverability of supporting research materials in ClinicalTrials.gov for US federally funded COVID-19 clinical studies.评估 ClinicalTrials.gov 中美国联邦资助的 COVID-19 临床研究支持研究材料的可发现性。
J Med Libr Assoc. 2024 Jul 1;112(3):250-260. doi: 10.5195/jmla.2024.1799. Epub 2024 Jul 29.
2
Discoverability of information on clinical trial data-sharing platforms.临床试验数据共享平台上信息的可发现性。
J Med Libr Assoc. 2021 Apr 1;109(2):240-247. doi: 10.5195/jmla.2021.992.
3
COVID-19 interventional trials: Analysis of data sharing intentions during a time of pandemic.COVID-19干预试验:大流行期间数据共享意图分析
Contemp Clin Trials. 2022 Apr;115:106709. doi: 10.1016/j.cct.2022.106709. Epub 2022 Feb 16.
4
COVID-19 trials: declarations of data sharing intentions at trial registration and at publication.COVID-19 临床试验:在试验注册和发表时声明数据共享意向。
Trials. 2021 Feb 18;22(1):153. doi: 10.1186/s13063-021-05104-z.
5
COVID-19 trials were not more likely to report intent to share individual data than non-COVID-19 trials in ClinicalTrials.gov.在 ClinicalTrials.gov 上,COVID-19 试验比非 COVID-19 试验更不可能报告分享个体数据的意向。
J Clin Epidemiol. 2023 Jun;158:10-17. doi: 10.1016/j.jclinepi.2023.03.015. Epub 2023 Mar 24.
6
Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data Packages.制药公司分享个体参与者数据包的异质性和效用。
JAMA Oncol. 2023 Dec 1;9(12):1621-1626. doi: 10.1001/jamaoncol.2023.3996.
7
Primed to comply: Individual participant data sharing statements on ClinicalTrials.gov.准备遵守:ClinicalTrials.gov 上的个体参与者数据共享声明。
PLoS One. 2020 Feb 18;15(2):e0226143. doi: 10.1371/journal.pone.0226143. eCollection 2020.
8
Sharing and reuse of individual participant data from clinical trials: principles and recommendations.从临床试验中分享和重用个体参与者数据:原则和建议。
BMJ Open. 2017 Dec 14;7(12):e018647. doi: 10.1136/bmjopen-2017-018647.
9
How should individual participant data (IPD) from publicly funded clinical trials be shared?来自公共资助临床试验的个体参与者数据(IPD)应如何共享?
BMC Med. 2015 Dec 17;13:298. doi: 10.1186/s12916-015-0532-z.
10
To share or not to share data: how valid are trials evaluating first-line ovulation induction for polycystic ovary syndrome?数据共享与否:评估多囊卵巢综合征一线促排卵治疗的试验有多可靠?
Hum Reprod Update. 2020 Nov 1;26(6):929-941. doi: 10.1093/humupd/dmaa031.

本文引用的文献

1
Transparency and reporting characteristics of COVID-19 randomized controlled trials.COVID-19 随机对照试验的透明度和报告特征。
BMC Med. 2022 Sep 26;20(1):363. doi: 10.1186/s12916-022-02567-y.
2
regCOVID: Tracking publications of registered COVID-19 studies.regCOVID:追踪已注册的 COVID-19 研究出版物。
BMC Med Res Methodol. 2022 Aug 10;22(1):221. doi: 10.1186/s12874-022-01703-9.
3
Many researchers say they'll share data - but don't.许多研究人员表示他们会分享数据,但实际上却没有这么做。
Nature. 2022 Jun;606(7916):853. doi: 10.1038/d41586-022-01692-1.
4
Results publications are inadequately linked to trial registrations: An automated pipeline and evaluation of German university medical centers.研究结果出版物与试验注册的链接不充分:德国大学医学中心的自动化管道和评估。
Clin Trials. 2022 Jun;19(3):337-346. doi: 10.1177/17407745221087456. Epub 2022 Apr 1.
5
COVID-19 interventional trials: Analysis of data sharing intentions during a time of pandemic.COVID-19干预试验:大流行期间数据共享意图分析
Contemp Clin Trials. 2022 Apr;115:106709. doi: 10.1016/j.cct.2022.106709. Epub 2022 Feb 16.
6
Medical journal requirements for clinical trial data sharing: Ripe for improvement.医学期刊对临床试验数据共享的要求:亟待改进。
PLoS Med. 2021 Oct 25;18(10):e1003844. doi: 10.1371/journal.pmed.1003844. eCollection 2021 Oct.
7
Status, use and impact of sharing individual participant data from clinical trials: a scoping review.临床试验个体参与者数据共享的现状、使用和影响:范围综述。
BMJ Open. 2021 Aug 18;11(8):e049228. doi: 10.1136/bmjopen-2021-049228.
8
Delays in reporting and publishing trial results during pandemics: cross sectional analysis of 2009 H1N1, 2014 Ebola, and 2016 Zika clinical trials.大流行期间临床试验结果报告和发表的延迟:对 2009 年 H1N1、2014 年埃博拉和 2016 年寨卡临床试验的横断面分析。
BMC Med Res Methodol. 2021 Jun 8;21(1):120. doi: 10.1186/s12874-021-01324-8.
9
COVID-19 trials: declarations of data sharing intentions at trial registration and at publication.COVID-19 临床试验:在试验注册和发表时声明数据共享意向。
Trials. 2021 Feb 18;22(1):153. doi: 10.1186/s13063-021-05104-z.
10
Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs.缺少临床试验数据:COVID-19 潜在药物主要数据中的证据空白。
Trials. 2021 Jan 15;22(1):59. doi: 10.1186/s13063-021-05024-y.